BETA DRUGS LIMITED Valuation
BETA · Healthcare · Current price ₹2,229.1
Is BETA DRUGS LIMITED undervalued?
DocStoX estimates the fair value of BETA DRUGS LIMITED at ₹702 per share, versus the current market price of ₹2,229. That puts the stock about -68.5% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹317), Relative P/E (₹1,600), Graham floor (₹471). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹317 (bear) to ₹702 (base) to ₹1,600 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
BETA DRUGS LIMITED trades at a P/E of 54.5x and a P/B of 9.1x, with a dividend yield of 0.0%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on BETA DRUGS LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.